PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsDoconexent
Doconexent
Doconexent is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target free fatty acid receptor 1, transient receptor potential cation channel subfamily A member 1, retinoic acid receptor RXR-alpha, and potassium channel subfamily K member 10.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
animi-3unapproved drug other2013-02-06
animi-3 with vitamin dunapproved drug other2011-05-23
bal-care dhaunapproved drug other2012-05-01
bal-care dha essentialunapproved drug other2012-05-01
bp vit 3unapproved drug other2023-10-11
c-nate dhaunapproved drug other2024-01-22
citranatal 90 dhaunapproved drug other2024-01-08
citranatal assureunapproved drug other2024-01-08
citranatal bloom dhaunapproved drug other2020-04-06
citranatal dhaunapproved drug other2020-07-28
Show 29 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
2529 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101C90.045972927153
LymphomaD008223C85.9521071713151
Plasma cell neoplasmsD05421943902726143
LeukemiaD007938C9540711626114
Lymphoid leukemiaD007945C912757142590
InflammationD007249MP_0001845411774773
Breast neoplasmsD001943EFO_0003869C5017251121870
Healthy volunteers/patients283423369
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.0193892665
ObesityD009765EFO_0001073E66.957424258
Show 210 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CarcinomaD002277C80.0315919698
NeoplasmsD009369C8058376894
Non-hodgkin lymphomaD008228C85.92840558
Non-small-cell lung carcinomaD002289222913255
Lung neoplasmsD008175HP_0100526C34.90133013655
B-cell chronic lymphocytic leukemiaD015451C91.12236753
Squamous cell carcinomaD00229416334551
B-cell lymphomaD0163932529241
Follicular lymphomaD008224C8213304139
MelanomaD0085452520138
Show 238 more
Indications Phases 2
Indications Phases 1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Muscular atrophyD009133HP_000320277
Vitamin d deficiencyD014808EFO_0003762E5566
Bone fracturesD050723EFO_0003931T14.855
CalculiD00213755
Body compositionD00182344
AffectD00033944
NephrolithiasisD053040N20.044
Kidney calculiD007669EFO_0004253N2044
Communicable diseasesD00314133
Sleep wake disordersD012893G4733
Show 293 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDoconexent
INNdoconexent
Description
All-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a docosahexaenoic acid having six cis-double bonds at positions 4, 7, 10, 13, 16 and 19. It has a role as a nutraceutical, an antineoplastic agent, a human metabolite, a Daphnia tenebrosa metabolite, a mouse metabolite and an algal metabolite. It is a docosahexaenoic acid and an omega-3 fatty acid. It is a conjugate acid of a (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate.
Classification
Small molecule
Drug class
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O
Identifiers
PDB
CAS-ID6217-54-5
RxCUI
ChEMBL IDCHEMBL367149
ChEBI ID28125
PubChem CID445580
DrugBankDB03756
UNII IDZAD9OKH9JC (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
KCNK10
KCNK10
Organism
Homo sapiens
Gene name
KCNK10
Gene synonyms
TREK2
NCBI Gene ID
Protein name
potassium channel subfamily K member 10
Protein synonyms
2P domain potassium channel TREK2, Outward rectifying potassium channel protein TREK-2, potassium channel TREK-2, potassium channel, subfamily K, member 10, potassium channel, two pore domain subfamily K, member 10, protein phosphatase 1, regulatory subunit 97, TREK-2 K(+) channel subunit, TWIK-related K+ channel 2
Uniprot ID
Mouse ortholog
Kcnk10 (72258)
potassium channel subfamily K member 10 (F6YU65)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 41,537 documents
View more details
Safety
Black-box Warning
Black-box warning for: Citranatal 90 dha, Citranatal assure, Citranatal dha, Citranatal essence, Citranatal harmony, Citranatal harmony 2.1, Citranatal harmony 3.0, Citranatal medley, Neonatal dha, Nestabs dha, Nestabs one, Pnv-dha, Pnv-omega, Pre-tabs dha, Prenaissance, Prenaissance plus, Prenatal plus multivitamin plus dha minicaps, Prenate dha, Prenate enhance, Prenate essential, Prenate mini, Prenate restore, Primacare, Reaphirm plant source dha, Select-ob plus dha, Tristart dha, Vitafol, Vitafol fe plus, Vitafol-ob plus dha
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
3,651 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use